Chemistry:Rezvilutamide
From HandWiki
Short description: Chemical compound
 | |
| Clinical data | |
|---|---|
| Other names | SHR3680 |
| Drug class | Nonsteroidal antiandrogen |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| UNII | |
| Chemical and physical data | |
| Formula | C22H20F3N3O4S |
| Molar mass | 479.47 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Rezvilutamide (INN),[1][2] sold under the brand name Ariane, is a nonsteroidal antiandrogen which is approved for the treatment of prostate cancer in China and is or was under development for the treatment of breast cancer.[3][4][5] It is a selective androgen receptor antagonist with reduced brain distribution compared to the structurally related nonsteroidal antiandrogen enzalutamide.[3][5] The drug was developed by Jiangsu Hengrui Medicine.[3] Other structural analogues of rezvilutamide that are also used as antiandrogens besides enzalutamide include apalutamide and proxalutamide.
References
- ↑ "Rezvilutamide". chemidplus. U.S. National Library of Medicine. https://chem.nlm.nih.gov/chemidplus/name/rezvilutamide.
- ↑ "International Nonproprietary Names for Pharmaceutical Substances (INN)". WHO. https://www.who.int/medicines/publications/druginformation/innlists/PL123.pdf.
- ↑ 3.0 3.1 3.2 "SHR 3680". AdisInsight. https://adisinsight.springer.com/drugs/800044844.
- ↑ "Rezvilutamide: First Approval". Drugs 83 (2): 189–193. January 2023. doi:10.1007/s40265-022-01831-y. PMID 36630077. https://figshare.com/articles/online_resource/Rezvilutamide_First_Approval/21766607.
- ↑ 5.0 5.1 "SHR3680, a novel antiandrogen, for the treatment of metastatic castration-resistant prostate cancer (mCRPC): A phase I/II study.". Journal of Clinical Oncology 38 (6_suppl): 90. 2020. doi:10.1200/JCO.2020.38.6_suppl.90.
 |  |
